Qiagen (NYSE:QGEN) Price Target Raised to $50.00 at JPMorgan Chase & Co.

Qiagen (NYSE:QGEN) had its price objective hoisted by JPMorgan Chase & Co. from $45.00 to $50.00 in a research report report published on Friday,Benzinga reports. They currently have an overweight rating on the stock.

Several other brokerages also recently commented on QGEN. Kepler Capital Markets set a $38.60 target price on shares of Qiagen and gave the stock a “hold” rating in a report on Thursday, June 25th. Barclays set a $40.00 price target on shares of Qiagen and gave the company an “equal weight” rating in a report on Friday. Zacks Research upgraded shares of Qiagen from a “strong sell” rating to a “hold” rating in a research report on Wednesday, April 29th. Weiss Ratings cut Qiagen from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, May 29th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $48.00 target price on shares of Qiagen in a research report on Thursday. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $43.34.

Qiagen Stock Up 1.3%

QGEN opened at $42.28 on Friday. The stock’s fifty day simple moving average is $39.43 and its 200 day simple moving average is $41.69. Qiagen has a 1-year low of $32.53 and a 1-year high of $57.81. The stock has a market cap of $8.71 billion, a PE ratio of 21.66, a price-to-earnings-growth ratio of 4.16 and a beta of 0.63. The company has a current ratio of 3.21, a quick ratio of 2.57 and a debt-to-equity ratio of 0.49.

Qiagen (NYSE:QGEN) last released its quarterly earnings data on Wednesday, August 5th. The company reported $0.62 EPS for the quarter, topping analysts’ consensus estimates of $0.60 by $0.02. Qiagen had a net margin of 19.49% and a return on equity of 14.24%. The firm had revenue of $535.04 million during the quarter, compared to analysts’ expectations of $527.50 million. During the same period in the previous year, the business posted $0.60 earnings per share. The company’s revenue for the quarter was up .2% compared to the same quarter last year. Qiagen has set its FY 2026 guidance at 2.430- EPS. As a group, research analysts expect that Qiagen will post 2.43 earnings per share for the current year.

Qiagen Increases Dividend

The firm also recently declared an annual dividend, which was paid on Tuesday, July 14th. Investors of record on Tuesday, July 7th were given a dividend of $0.35 per share. This is a positive change from Qiagen’s previous annual dividend of $0.26. This represents a yield of 90.0%. The ex-dividend date of this dividend was Tuesday, July 7th. Qiagen’s payout ratio is 18.32%.

Institutional Trading of Qiagen

Several hedge funds and other institutional investors have recently bought and sold shares of QGEN. Canvas Wealth Advisors LLC grew its position in shares of Qiagen by 90.2% during the 2nd quarter. Canvas Wealth Advisors LLC now owns 30,119 shares of the company’s stock worth $1,178,000 after purchasing an additional 14,281 shares in the last quarter. Handelsbanken Fonder AB bought a new position in shares of Qiagen during the second quarter worth approximately $2,909,000. GAMMA Investing LLC raised its position in shares of Qiagen by 70.4% in the second quarter. GAMMA Investing LLC now owns 3,521 shares of the company’s stock valued at $138,000 after buying an additional 1,455 shares in the last quarter. Hilltop National Bank acquired a new stake in shares of Qiagen in the second quarter valued at approximately $50,000. Finally, Groupama Asset Managment bought a new stake in shares of Qiagen in the first quarter valued at approximately $500,000. Institutional investors and hedge funds own 70.00% of the company’s stock.

Qiagen Company Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.